Mozobil® (Plerixafor, AMD3100), 10 years after its approval by the US Food and Drug Administration.
De Clercq E.
Antivir Chem Chemother · review-article; review; journal article · DOI 10.1177/2040206619829382 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för plerixafor. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
14 träffarDefining the in vivo characteristics of acute myeloid leukemia cells behavior by intravital imaging.
Duarte D, Amarteifio S, Ang H, Kong IY, Ruivo N, Pruessner G, Hawkins ED, Lo Celso C.
Immunol Cell Biol · brief-report; research support, non-u.s. gov't; journal article · DOI 10.1111/imcb.12216Forkhead box C1 boosts triple-negative breast cancer metastasis through activating the transcription of chemokine receptor-4.
Pan H, Peng Z, Lin J, Ren X, Zhang G, Cui Y.
Cancer Sci · research-article; journal article · DOI 10.1111/cas.13823Plerixafor and related macrocyclic amines are potential drug candidates in treatment of malaria by "filling the flap" region of plasmepsin enzymes.
Abiri A.
Med Hypotheses · journal article · DOI 10.1016/j.mehy.2018.06.020Inhibition of HIV Fusion by Small Molecule Agonists through Efficacy-Engineering of CXCR4.
Berg C, Daugvilaite V, Steen A, Jørgensen AS, Våbenø J, Rosenkilde MM.
ACS Chem Biol · research support, non-u.s. gov't; journal article · DOI 10.1021/acschembio.8b00061Evaluation of Hematopoietic Stem Cell Mobilization Rates with Early Plerixafor Administration for Adult Stem Cell Transplantation.
Stover JT, Shaw JR, Kuchibhatla M, Horwitz ME, Engemann AM.
Biol Blood Marrow Transplant · comparative study; clinical trial; journal article · DOI 10.1016/j.bbmt.2017.04.007Chemokines and cocaine: CXCR4 receptor antagonist AMD3100 attenuates cocaine place preference and locomotor stimulation in rats.
Kim J, Connelly KL, Unterwald EM, Rawls SM.
Brain Behav Immun · research-article; journal article · DOI 10.1016/j.bbi.2016.08.015The interaction of Mozobil™ with carboxylates.
Amendola V, Bergamaschi G, Fabbrizzi L, Licchelli M, Mangano C.
Org Biomol Chem · research support, non-u.s. gov't; journal article · DOI 10.1039/c5ob01704aCXCR4-Targeted Nanocarriers for Triple Negative Breast Cancers.
Misra AC, Luker KE, Durmaz H, Luker GD, Lahann J.
Biomacromolecules · research-article; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1021/acs.biomac.5b00653AMD3100/CXCR4 Inhibitor.
De Clercq E.
Front Immunol · review-article; review; journal article · DOI 10.3389/fimmu.2015.00276Physiology and pharmacology of plerixafor.
Fricker SP.
Transfus Med Hemother · review-article; review; journal article · DOI 10.1159/000354132Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells.
Uy GL, Rettig MP, Cashen AF.
Expert Opin Biol Ther · research support, non-u.s. gov't; review; journal article · DOI 10.1517/14712598.8.11.1797Plerixafor: AMD 3100, AMD3100, JM 3100, SDZ SID 791.
Författaruppgift saknas
Drugs R D · journal article · DOI 10.2165/00126839-200708020-00006Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100.
De Clercq E, Yamamoto N, Pauwels R, Balzarini J, Witvrouw M, De Vreese K, Debyser Z, Rosenwirth B, Peichl P, Datema R.
Antimicrob Agents Chemother · research support, non-u.s. gov't; research-article; journal article · DOI 10.1128/aac.38.4.668